(RCKT) Rocket Pharmaceuticals - Ratings and Ratios
Gene Therapy, Rare Disease, Cardiac Disorder, Biotechnology Product
RCKT EPS (Earnings per Share)
RCKT Revenue
Description: RCKT Rocket Pharmaceuticals
Rocket Pharmaceuticals Inc (NASDAQ:RCKT) is a late-stage biotechnology company focused on developing gene therapies for rare and devastating diseases. The companys pipeline includes several promising programs targeting cardiac disorders and genetic diseases, such as Danon disease, Leukocyte Adhesion Deficiency-I, and Fanconi Anemia.
From a business perspective, RCKT has established strategic partnerships with reputable institutions, including UCL Business PLC, The Regents of the University of California, and REGENXBIO, Inc., to advance its research and development efforts. These collaborations can be seen as a validation of the companys technology and approach.
Evaluating RCKTs performance using key performance indicators (KPIs), we can observe that the companys market capitalization stands at approximately $272 million. The absence of a price-to-earnings (P/E) ratio indicates that the company is not yet profitable. Return on Equity (RoE) is negative at -64.92%, suggesting significant investment in research and development. To gauge the companys progress, we can monitor metrics such as cash burn rate, pipeline development milestones, and partnerships.
Notably, RCKTs gene therapy programs are in various stages of development, with some, like RP-A501 for Danon disease, in Phase 2 trials, while others, such as RP-L201 for Leukocyte Adhesion Deficiency-I, are also advancing through the clinical pipeline. The success of these programs will be crucial in driving the companys growth and valuation.
To further assess RCKTs potential, its essential to track the progress of its pipeline, upcoming clinical trial results, and any new partnerships or collaborations that may be announced. Additionally, monitoring the companys cash reserves and burn rate will provide insight into its ability to fund its research and development efforts.
RCKT Stock Overview
| Market Cap in USD | 349m |
| Sub-Industry | Biotechnology |
| IPO / Inception | 2015-02-18 |
RCKT Stock Ratings
| Growth Rating | -85.7% |
| Fundamental | 35.7% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | -88.3% |
| Analyst Rating | 4.61 of 5 |
RCKT Dividends
Currently no dividends paidRCKT Growth Ratios
| Growth Correlation 3m | 67.2% |
| Growth Correlation 12m | -93.8% |
| Growth Correlation 5y | -65.1% |
| CAGR 5y | -37.99% |
| CAGR/Max DD 3y | -0.41 |
| CAGR/Mean DD 3y | -1.42 |
| Sharpe Ratio 12m | -2.33 |
| Alpha | 0.06 |
| Beta | 0.724 |
| Volatility | 58.76% |
| Current Volume | 2630.4k |
| Average Volume 20d | 2068k |
| Stop Loss | 2.8 (-7.6%) |
| Signal | -2.11 |
Piotroski VR‑10 (Strict, 0-10) 0.0
| Net Income (-257.3m TTM) > 0 and > 6% of Revenue (6% = 551.2k TTM) |
| FCFTA -0.51 (>2.0%) and ΔFCFTA -3.86pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 2545 % (prev 2474 %; Δ 70.56pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -0.48 (>3.0%) and CFO -203.8m > Net Income -257.3m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 6.39 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (111.0m) change vs 12m ago 18.43% (target <= -2.0% for YES) |
| Gross Margin 13.81% (prev -11.62%; Δ 25.43pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 2.12% (prev 2.31%; Δ -0.19pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -135.2 (EBITDA TTM -245.1m / Interest Expense TTM 1.89m) >= 6 (WARN >= 3) |
Altman Z'' -31.95
| (A) 0.56 = (Total Current Assets 277.2m - Total Current Liabilities 43.4m) / Total Assets 421.0m |
| (B) -3.20 = Retained Earnings (Balance) -1.35b / Total Assets 421.0m |
| warn (B) unusual magnitude: -3.20 — check mapping/units |
| (C) -0.59 = EBIT TTM -255.4m / Avg Total Assets 433.7m |
| (D) -20.18 = Book Value of Equity -1.35b / Total Liabilities 66.8m |
| Total Rating: -31.95 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 35.68
| 1. Piotroski 0.0pt = -5.0 |
| 2. FCF Yield data missing |
| 3. FCF Margin data missing |
| 4. Debt/Equity 0.07 = 2.50 |
| 5. Debt/Ebitda -0.11 = -2.50 |
| 6. ROIC - WACC (= -73.69)% = -12.50 |
| 7. RoE -66.00% = -2.50 |
| 8. Rev. Trend 18.93% = 1.42 |
| 9. EPS Trend 85.17% = 4.26 |
What is the price of RCKT shares?
Over the past week, the price has changed by -4.72%, over one month by +0.00%, over three months by +11.40% and over the past year by -86.10%.
Is Rocket Pharmaceuticals a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of RCKT is around 2.66 USD . This means that RCKT is currently overvalued and has a potential downside of -12.21%.
Is RCKT a buy, sell or hold?
- Strong Buy: 12
- Buy: 5
- Hold: 1
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the RCKT price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 7.9 | 159.4% |
| Analysts Target Price | 7.9 | 159.4% |
| ValueRay Target Price | 3 | -2.3% |
Last update: 2025-09-05 04:57
RCKT Fundamental Data Overview
CCE Cash And Equivalents = 271.5m USD (Cash And Short Term Investments, last quarter)
P/B = 1.0129
Beta = 0.623
Revenue TTM = 9.19m USD
EBIT TTM = -255.4m USD
EBITDA TTM = -245.1m USD
Long Term Debt = 23.4m USD (from nonCurrentLiabilitiesTotal, last quarter)
Short Term Debt = 2.89m USD (from shortTermDebt, last quarter)
Debt = 26.3m USD (Calculated: Short Term 2.89m + Long Term 23.4m)
Net Debt = -7.62m USD (from netDebt column, last quarter)
Enterprise Value = 103.3m USD (348.5m + Debt 26.3m - CCE 271.5m)
Interest Coverage Ratio = -135.2 (Ebit TTM -255.4m / Interest Expense TTM 1.89m)
FCF Yield = -208.7% (FCF TTM -215.6m / Enterprise Value 103.3m)
FCF Margin = -2347 % (FCF TTM -215.6m / Revenue TTM 9.19m)
Net Margin = -2801 % (Net Income TTM -257.3m / Revenue TTM 9.19m)
Gross Margin = 13.81% ((Revenue TTM 9.19m - Cost of Revenue TTM 7.92m) / Revenue TTM)
Tobins Q-Ratio = -0.08 (set to none) (Enterprise Value 103.3m / Book Value Of Equity -1.35b)
Interest Expense / Debt = 1.80% (Interest Expense 473.0k / Debt 26.3m)
Taxrate = 21.0% (US default)
NOPAT = -255.4m (EBIT -255.4m, no tax applied on loss)
Current Ratio = 6.39 (Total Current Assets 277.2m / Total Current Liabilities 43.4m)
Debt / Equity = 0.07 (Debt 26.3m / last Quarter total Stockholder Equity 354.2m)
Debt / EBITDA = -0.11 (Net Debt -7.62m / EBITDA -245.1m)
Debt / FCF = -0.12 (Debt 26.3m / FCF TTM -215.6m)
Total Stockholder Equity = 389.8m (last 4 quarters mean)
RoA = -61.12% (Net Income -257.3m, Total Assets 421.0m )
RoE = -66.00% (Net Income TTM -257.3m / Total Stockholder Equity 389.8m)
RoCE = -61.81% (Ebit -255.4m / (Equity 389.8m + L.T.Debt 23.4m))
RoIC = -65.52% (NOPAT -255.4m / Invested Capital 389.8m)
WACC = 8.17% (E(348.5m)/V(374.8m) * Re(8.68%)) + (D(26.3m)/V(374.8m) * Rd(1.80%) * (1-Tc(0.21)))
Shares Correlation 3-Years: 100.00 | Cagr: 4.81%
Discount Rate = 8.68% (= CAPM, Blume Beta Adj.)
Fair Price DCF = unknown (Cash Flow -215.6m)
EPS Correlation: 85.17 | EPS CAGR: 49.99% | SUE: -0.97 | # QB: 0
Revenue Correlation: 18.93 | Revenue CAGR: 0.0% | SUE: -4.0 | # QB: 0
Additional Sources for RCKT Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle